Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -11.42% is 95% above its 5-year average of -215.28%, near the high end of its 5-year range (-1292.99%–-4.63%).
12.77% above its 12-month average of -13.09%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -16.57%.
EBITDA MARGIN
-11.42%
EBITDA MARGIN AVG TTM
-13.09%
EBITDA MARGIN AVG 3Y
-15.25%
EBITDA MARGIN AVG 5Y
-215.28%
EBITDA MARGIN AVG 10Y
-319.25%
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+12.77%
CURRENT VS 3Y AVG
+25.10%
CURRENT VS 5Y AVG
+94.70%
CURRENT VS 10Y AVG
+96.42%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Sunshine Biopharma, Inc.
Market Cap
$946332.00
EBITDA Margin
-11.42%
TTM Avg
-13.09%
3Y Avg
-15.25%
5Y Avg
-215.28%
Market Cap
$901902.00
EBITDA Margin
1710.10%
TTM Avg
8440.35%
3Y Avg
4905.18%
5Y Avg
4832.78%
Market Cap
$1.01M
EBITDA Margin
-182712.72%
TTM Avg
-182712.72%
3Y Avg
-182712.72%
5Y Avg
-182712.72%
Market Cap
$868077.00
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$838843.00
EBITDA Margin
-3618.46%
TTM Avg
-3618.46%
3Y Avg
-3618.46%
5Y Avg
-3618.46%
Market Cap
$835994.00
EBITDA Margin
-1.14%
TTM Avg
1.51%
3Y Avg
-2.34%
5Y Avg
-2.59%
Market Cap
$824550.00
EBITDA Margin
-148.44%
TTM Avg
-191.64%
3Y Avg
-1422.24%
5Y Avg
-1921.61%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Sunshine Biopharma, Inc. (SBFM) | $946332.00 | -11.42% | -13.09% | -15.25% | -215.28% |
| GlucoTrack, Inc. (GCTK)vs › | $901902.00 | 1710.10% | 8440.35% | 4905.18% | 4832.78% |
| Aspire Biopharma Holdings, Inc. (ASBP)vs › | $1.01M | -182712.72% | -182712.72% | -182712.72% | -182712.72% |
| Bone Biologics Corporation (BBLG)vs › | $868077.00 | N/A | N/A | N/A | N/A |
| Bluejay Diagnostics, Inc. (BJDX)vs › | $838843.00 | -3618.46% | -3618.46% | -3618.46% | -3618.46% |
| Ridgetech, Inc. (RDGT)vs › | $835994.00 | -1.14% | 1.51% | -2.34% | -2.59% |
| Decoy Therapeutics Inc. (DCOY)vs › | $824550.00 | -148.44% | -191.64% | -1422.24% | -1921.61% |
| Clearmind Medicine Inc. (CMND)vs › | $1.08M | N/A | N/A | N/A | N/A |
| Propanc Biopharma, Inc. (PPCB)vs › | $1.12M | N/A | N/A | N/A | N/A |
| Cellyan Biotechnology Co., Ltd (HKPD)vs › | $1.13M | -6.76% | -0.42% | 7.09% | 7.09% |
Gross Margin
29.8%
EBITDA Margin
-11.4%
Operating Margin
-14.7%
Net Margin
-16.5%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -16.57% |
| 2026-03-31 | -16.30% |
| 2025-12-31 | -18.18% |
| 2025-09-30 | -4.63% |
| 2025-06-30 | -9.78% |
| 2025-03-31 | -13.83% |
| 2024-12-31 | -20.56% |
| 2024-09-30 | -12.35% |
| 2024-06-30 | -13.09% |
| 2024-03-31 | -17.34% |
| 2023-12-31 | -14.91% |
| 2023-09-30 | -12.46% |
| 2023-06-30 | -17.61% |
| 2023-03-31 | -36.66% |
| 2022-12-31 | -592.53% |
| 2022-09-30 | -1292.99% |
| 2022-06-30 | -461.40% |
| 2022-03-31 | -994.95% |
| 2021-12-31 | -324.78% |
| 2021-09-30 | -978.79% |
| 2021-06-30 | -728.91% |
| 2021-03-31 | -3176.55% |
| 2020-12-31 | -1212.85% |
| 2020-09-30 | -371.92% |
| 2020-06-30 | -827.98% |
| 2020-03-31 | -305.07% |
| 2019-12-31 | -2341.02% |
| 2019-09-30 | -2718.63% |
| 2019-03-31 | -51327.18% |
| 2018-12-31 | -127.89% |
| 2018-03-31 | -175.45% |
| 2015-06-30 | -21554.86% |
